Deutsch English Français

Contact

EP4193146

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP4193146

EP4193146 - END STAGE RENAL DISEASE BIOMARKER PANEL [Right-click to bookmark this link]
Status	Request for examination was made Status updated on 12.05.2023 Database last updated on 11.04.2026
Former	The international publication has been made Status updated on 11.02.2022
Most recent event Tooltip	27.08.2025	New entry: Decision on request for further processing
	27.08.2025	New entry: Renewal fee paid
Applicant(s)	For all designated states Joslin Diabetes Center, Inc. One Joslin Place Boston, MA 02215 / US
	[2023/24]
Inventor(s)	01 / KROLEWSKI, Andrzej Needham, Massachusetts 26158 / US
	[2023/24]
Representative(s)	Longland, Emma Louise, et al Venner Shipley LLP 406 Science Park Milton Road Cambridge CB4 0WW / GB
	[N/P]
Former [2023/24]	Longland, Emma Louise, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge CB4 0WZ / GB
Application number, filing date	21852659.8	05.08.2021
	[2023/24]
	WO2021US44658
Priority number, date	US202063061616P	05.08.2020 Original published format: US 202063061616 P
	US202163197120P	04.06.2021 Original published format: US 202163197120 P
	[2023/24]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2022031920
	Date:	10.02.2022
	Language:	EN
	[2022/06]
	Type:	A2 Application without search report
	No.:	EP4193146
	Date:	14.06.2023
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 10.02.2022 takes the place of the publication of the European patent application.
	[2023/24]
Search report(s)	International search report - published on:	US	10.03.2022
	(Supplementary) European search report - dispatched on:	EP	11.11.2024
Classification	IPC:	G01N33/50, G01N33/68	[2023/24]
	CPC:	G01N33/6893 (EP,US); G01N2333/70596 (EP); G01N2333/7151 (EP); G01N2800/347 (EP,US); G01N2800/50 (EP,US); G01N2800/52 (US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/24]
Title	German:	BIOMARKERTAFEL FÜR TERMINALE NIERENERKRANKUNG	[2023/24]
	English:	END STAGE RENAL DISEASE BIOMARKER PANEL	[2023/24]
	French:	PANNEAU DE BIOMARQUEUR DE MALADIE RÉNALE DE STADE TERMINAL	[2023/24]
Entry into regional phase	03.03.2023	National basic fee paid
	03.03.2023	Search fee paid
	03.03.2023	Designation fee(s) paid
	03.03.2023	Examination fee paid
Examination procedure	03.03.2023	Examination requested [2023/24]
	28.05.2025	Date on which the examining division has become responsible
	16.06.2025	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
	16.08.2025	Amendment by applicant (claims and/or description)
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
	16.08.2025	Request for further processing filed
	16.08.2025	Full payment received (date of receipt of payment) Request granted
	26.08.2025	Decision despatched
Fees paid	Renewal fee
	28.08.2023	Renewal fee patent year 03
	27.08.2024	Renewal fee patent year 04
	27.08.2025	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XI] WO2018069487 (INST NAT SANTE RECH MED et al.) [X] 1-3,5,7-12,15-17,20,21 * pages 1,3,8; figure 2; claims 1,6 *[I] 4,6,13,14,18,19
		[XI] US9791452 (NIEWCZAS MONIKA A et al.) [X] 1-5,7-13,15-17,20,21 * pages 1,6,8; example 4; claims 1-3 *[I] 6,14,18,19
		[XAI] BARR ELIZABETH L.M. ET AL: "High Baseline Levels of Tumor Necrosis Factor Receptor 1 Are Associated With Progression of Kidney Disease in Indigenous Australians With Diabetes: The eGFR Follow-up Study", DIABETES CARE, vol. 41, no. 4, 24 January 2018 (2018-01-24), US, pages 739 - 747, XP093181119, ISSN: 0149-5992, Retrieved from the Internet DOI: 10.2337/dc17-1919 [X] 1-3,5,8-12,15,20,21 * page 739 - page 740 [A] 17-19 [I] 4,6,7,13,14,16 DOI:* http://dx.doi.org/10.2337/dc17-1919
	International search	[XY] US2017115310 (COLHOUN HELEN et al.) [X] 1-5, 35-41, 52-54 * abstract; para. [0006]-[0014]; [0018]; [0084]; [0129]-[0132]; [0146]-[0147]; [0156]-[0168]; [0179]; [0192] *[Y] 18-22, 43-45
		[Y] KR20160084353 (UNIV KYUNG HEE UNIV IND COOP GROUP et al.) [Y] 18-22, 43-45 * [English translation] abstract; para [0047]; [0078], Table 10 *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.